Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long‐term follow‐up of the randomized, open‐label, phase 3 CheckMate 025 trial
Journal article published in 2020 by
Robert J. Motzer 
,
Bernard Escudier,
Saby George,
Hans J. Hammers,
Sandhya Srinivas,
Scott S. Tykodi,
Jeffrey A. Sosman,
Elizabeth R. Plimack,
Giuseppe Procopio ,
David F. McDermott,
Daniel Castellano,
Toni K. Choueiri ,
Frede Donskov,
Howard Gurney,
Stéphane Oudard
and other authors.
,
Bernard Escudier,
Saby George,
Hans J. Hammers,
Sandhya Srinivas,
Scott S. Tykodi,
Jeffrey A. Sosman,
Elizabeth R. Plimack,
Giuseppe Procopio ,
David F. McDermott,
Daniel Castellano,
Toni K. Choueiri ,
Frede Donskov,
Howard Gurney,
Stéphane Oudard
and other authors.
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 